Therese Liechtenstein

Therese Liechtenstein serves as the Investment Director at 4BIO Capital since November 2024 and has held various senior roles in the biotech investment sector, including Senior Investment Director at M Ventures from July 2018 to September 2024. Additional board positions include serving as a Board Member at ReproNovo, DISCO Pharmaceuticals GmbH, Future Fertility, Altoida, Inc., Theolytics, and Anavo Therapeutics BV from 2021 to 2024, along with a Board Observer role at Plexium. Liechtenstein's academic background includes a PhD in Cancer Immunology and Immunotherapy from UCL (2012-2015), an MSc in Medical Biology from the University of Amsterdam (2010-2012), and a BA in Biology and Business Studies from New York University (2006-2010).